Remuzzi G, Misiani R, Marchesi D, Livio M, Mecca G, de Gaetano G, Donati M B
Lancet. 1978 Oct 21;2(8095):871-2. doi: 10.1016/s0140-6736(78)91573-8.
It is suggested that patients with the haemolytic-uraemic syndrome and related disorders (such as thrombotic thrombocytopenic purpura) lack a plasma factor which stimulates prostacyclin (P.G.I2) activity. Normal plasma would supply the missing factor and is a rational treatment for some life-threatening symptoms (thrombocytopenia, haemolytic anaemia, hypertension) of this syndrome.
有人提出，溶血尿毒综合征及相关病症（如血栓性血小板减少性紫癜）患者缺乏一种刺激前列环素（P.G.I2）活性的血浆因子。正常血浆可提供这种缺失的因子，是治疗该综合征某些危及生命症状（血小板减少、溶血性贫血、高血压）的合理方法。
